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France has been at the epicenter of the worldwide debate about hydroxychloroquine, as the 
main publications advocating its use to treat COVID-19 come from a research unit led by 
Didier Raoult in Marseille. The objective of this study was to determine the impact of this 
debate on the opinions and practices of French primary care physicians. 
 
Methods 
At the peak of the pandemic in France, we conducted an online cross-sectional questionnaire 
survey among a national panel of 2940 self-employed PCPs. The questionnaire assessed their 
trust in the health authorities, their opinions about the official guidelines for the management 
of patients with COVID-19, and any difficulties in dealing with these patients requesting 
prescriptions for hydroxychloroquine. 
 
Results 
In all, 1200 PCPs (40.8%) completed the questionnaire. We found that physicians in the areas 
most strongly affected by the epidemic (40%) or closest to the epicentre of the controversy 
(50%) reported that the hydroxychloroquine debate had made it difficult for them to deal with 
patients' treatment requests. Their overall adherence to official recommendations was also 
lower (RR=0.61). Reported difficulties were less frequent among PCPs in group compared 
with solo practices (RR=0.67).  
 
Conclusions 
The hydroxychloroquine debate created dilemmas for a significant portion of PCPs in a 
context of undermined trust in the health authorities. In due course, it will be necessary to 
examine the conditions producing so strong a conflict to ensure better preparation not only 





COVID-19, coronavirus, primary care, hydroxychloroquine. 
 
Abbreviations 
GP: General practitioner 
 
Introduction 
Epidemics create a rush for treatment. In this context, the endorsement of pharmaceutical 
drugs by public figures before proper evaluation can have dire consequences, as was the case 
with hydroxychloroquine. In the USA, President Trump’s unbridled advocacy led to an 
increase in its off-label sales, shortages for patients with indications for which its efficacy is 
established, and an increase in its reported cardiac side effects1. France has been at the 
epicenter of worldwide debates about this drug, as the main advocacy for its use against 
COVID-19 have come from a team of infectiologists led by Didier Raoult in Marseille2. 
Hydroxychloroquine's continued prominence in the news since mid-March has persuaded a 
significant proportion of French public to believe in its efficacy: 48% of them would like to 
receive the treatment if they were affected3. 
The impact of these highly visible debates is not restricted to patients, however. It also 
affects healthcare providers. Doctors may be affected by patients' requests or demands for a 
prescription for hydroxychloroquine, or swayed by the arguments presented in favor of its 
prescription to patients with COVID-19, despite contrary recommendations from the French 
public health authorities4. As studies show, doctors can espouse beliefs at odds with public 
health authorities’ recommendations and scientific consensus on various subjects ranging 
from vaccination5 to Lyme disease6. 
We conducted a flash survey on COVID-19 among a representative sample of 1200 
French self-employed general practitioners (GPs)—who were responsible for diagnosing and 
managing patients with COVID-19 in the community—to better understand the impact of 
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controversies of their practices. The present article sought to evaluate the extent to which 
they may face dilemmas in epidemic contexts where uncertainty is substantial, prominent 
experts disagree, and medical issues become politicized. 
 
Methods 
We used data collected from a national panel of 3300 self-employed GPs established in late 
2018. They were randomly selected from the French National Registry of Health Care 
Workers (Health Ministry). Demographic and professional characteristics of participants 
were collected at inclusion in the panel. The 2940 GPs (89.1%) still participating in the panel 
in April 2020 were asked to take this online cross-sectional survey. The questionnaire 
included the following question: "Does the current controversy over hydroxychloroquine 
make it difficult for you to respond to requests for treatment by your patients positive for 
COVID-19?" (yes/no/don’t know). It also collected participants' opinions about the official 
recommendations of the French health authorities on the diagnosis and management of 
patients with COVID-19: are they clear, sufficient, applicable, or changed too often, 4 items, 
yes/no, Cronbach alpha=0.66). We weighted data according to GPs’ age, gender and 
workload to obtain a sample representative of this population for these variables.  
 
Results 
From April 9 to April 20, 1200 GPs (40.8%) completed the questionnaire. More than 1 doctor 
in 4 (27%) reported difficulties with their patients due to this polemic. This figure was 
significantly higher in Southeastern France (50%), where Pr. Raoult's institute is located, and 
in the areas most affected by the epidemic (40%), compared with 25% in those least affected 
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(Table 2). This opinion was significantly less frequent in group practices than in solo 
practices (aRR 0.67, 95% CI 0.49 to 0.90).  
Moreover, the official recommendations of the Ministry of Health site for the overall 
management of patients with suspected or proven Covid-19 infection were clear for 69.5% of 
the doctors. More than half considered them sufficient (54.7%) or applicable (56.7%), but 
64.2% felt that they changed too frequently. Multiple Poisson regression adjusted on age, 
gender, and region found that overall adherence to these recommendations (score adding up 
GPs’ answers to the 4 items; range 0–4) was significantly lower (aRR 0.61, 95% CI 0.47 to 
0.80) among those physicians who felt that the controversy about hydroxychloroquine made 
it difficult for them to respond to these patients' requests (Table 1).  
 
Discussion 
These results are an indicator of the scale of the consequences of the controversy around 
hydroxychloroquine. Physicians reported more frequent difficulties in the areas most strongly 
affected by the epidemic and especially those closest to the epicenter of the controversy than 
elsewhere. In these areas, physicians saw more frequent requests from patients positive for 
SARS-CoV-2 for the treatment, linked to the hope inspired by the claimed therapeutic 
benefits of hydroxychloroquine. 
More broadly, physicians increasingly face patients who make specific requests or 
even demands for treatment, based on their own search for information and on non-medical 
considerations (psychological, cultural, even political with the demand for greater local 
autonomy). This process of empowerment7 through which patients have strengthened their 
willingness and ability to take effective care of their health has been underway in Western 
countries for several decades.  
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 The gap between the requests of patients and the guidelines of the health authorities 
may have created a dilemma among GPs, reinforced by the intensity of the disagreements 
between experts, the media coverage, and politicization of the debates, as well as the fairly 
widespread mistrust of the government8. Dialogue with colleagues, facilitated in group 
offices, might have reduced the perception of this dilemma and probably also made it 
possible to better organize the response to patients' requests for this treatment or medication.  
Nonetheless, the negative association between the frequency of this problem among 
physicians and their confidence in the official management guidelines for COVID-19 
suggests a second type of explanation. The physicians themselves may sufficiently convinced 
by the evidence of the hydroxychloroquine defenders to question the official guidelines. 
Indeed, the debate as it took place in France opposed leading researchers against one another 
rather than representatives of mainstream science against outsiders; it is therefore different 
from the controversy about the association between autism and the MMR vaccine that has 
raged for a decade9. On one side were experts who considered it essential to await the results 
of randomized controlled trials before prescribing hydroxychloroquine to patients with 
COVID-19. On the other side, Didier Raoult, backed by other medical school professors, 
claimed that a) the preliminary data and long experience with this substance for the 
conditions were sufficient to judge its safety, b) an RCT would take too much time and is not 
appropriate for the production of knowledge for decision-making in emergency situations, 
and c) the physician's duty is to try to treat the patient. These arguments are particularly likely 
to have convinced some GPs who in situations of uncertainty would tend to rely on their own 
judgment rather than clinical practice guidelines10. Our experience in recent months with 
physicians in southeastern France shows broad support by GPs, particularly in Marseilles, for 
the combined therapy recommended by the IHU. Many GPs have taken up the arguments of 
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In due course, it will be necessary to examine the conditions producing so strong a conflict 
and its societal causes as well as its public health and social consequences. This reflection 
will need to involve all parties, including GPs and not only specialist scientists, to ensure 
better preparation for health management and for knowledge production in the not unlikely 
event of a future epidemic.  
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Table 1. Factors associated, among general practitioners, with agreement that the 
controversy over hydroxychloroquine made it difficult for them to deal with requests 
for the treatment from patients who tested positive for COVID-19, modified Poisson 
regression, weighted data, April 2020 (Ref. Do not agree, N=1151) 
 
Factors aRR 95% CI 
Sex (ref. Male)   
Female 1.16 [0.87,1.55] 
Region (ref. Rest of France)   
South-eastern France 2.10*** [1.58,2.80] 
Western France (Pays de la Loire) 0.86 [0.58,1.27] 
Intensity of the Covid-19 epidemic in French districts (ref. Low)   
Moderate 1.14 [0.77,1.70] 
High 1.79** [1.17,2.74] 
Age (ref. < 50 years old)   
50-59 0.80 [0.55,1.15] 
>= 60 0.94 [0.66,1.33] 
General Practitioners density (ref. low)   
Yes 1.18 [0.86,1.61] 
Type of practice (ref. solo)   
Group 0.67** [0.49,0.90] 
Workload (ref. Min-Q1)   
Q1-Q3 1.03 [0.76,1.41] 
Q3-Max 1.23 [0.85,1.78] 
Score of trust in the Health Ministry to manage the Covid-19 
epidemic [0-12] (ref. Low [0-7])   
High [8-12] 0.80 [0.59,1.09] 
P-value: * < 0.05 ; ** < 0.01 ; *** < 0.001 
   
 
